

# UTILITY PATENT APPLICATION TRANSMITTAL


(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 18, 2003

Date of Deposit

Signature

EL 816576645 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0063 US NP  
INVENTORS: RITZELER, et al.  
TITLE: INDOLE DERIVATIVES OR BENZIMIDAZOLE  
DERIVATIVES FOR MODULATING I<sub>K</sub>B KINASE

03970 U.S. PTO  
10/642970  
08/18/03  


## APPLICATION ELEMENTS

- |   |              |                                 |
|---|--------------|---------------------------------|
| 1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)<br><i>(Submit an original and a duplicate for fee processing)</i>  | Total Pages  | <input type="text" value="53"/> |
| 2. <input checked="" type="checkbox"/> Specification<br><i>(preferred arrangement set forth below)</i><br>- Descriptive title of the Invention<br>- Cross References to Related Applications<br>- Statement Regarding Fed sponsored R & D<br>- Reference to Microfiche Appendix<br>- Background of the Invention<br>- Brief Summary of the Invention<br>- Brief Description of the Drawings <i>(if filed)</i><br>- Detailed Description<br>- Claim(s)<br>- Abstract of the Disclosure | Total Pages  | <input type="text" value="53"/> |
| 3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113)  | Total Sheets | <input type="text"/>            |
| 4. Oath or Declaration  | Total Pages  | <input type="text" value="2"/>  |
| a. <input checked="" type="checkbox"/> Newly unexecuted (original or copy)  |              |                                 |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))  |              |                                 |
| i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u><br>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).  |              |                                 |
| 5. Power of Attorney  | Total Pages  | <input type="text"/>            |
| a. <input type="checkbox"/> Newly executed (original or copy)   |              |                                 |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))  |              |                                 |
| 6. <input type="checkbox"/> Microfiche Computer Program (Appendix)  |              |                                 |

7. Nucleotide and/or Amino Acid Sequence Submission  
*(if applicable, all necessary)*
- Computer Readable Copy
  - Paper Copy (identical to computer copy)
  - Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation     Divisional     Continuation-in-part

of prior application no: \_\_\_\_\_, filed \_\_\_\_\_

Examiner \_\_\_\_\_, Group/Art Unit \_\_\_\_\_.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/434,749, filed December 19, 2002. (The cross reference has been/will be inserted on page one of the specification).

**Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

#### ACCOMPANYING APPLICATION PARTS

7.  Assignment Papers (*cover sheet & document(s)*)
8.  37 CFR §3.73(b) Statement  
*(when there is an assignee)*
9.  Verified English Translation Document (*if applicable*)
10.  Information Disclosure Statement (IDS)/PTO-1449       Copies of IDS Citations
11.  Preliminary Amendment
12.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
13.  \*Small Entity Statement(s)       Statement filed in prior application,  
*(PTO/SB/09-12)* Status still proper and desired
14.  Certified Copy of Priority Document(s) – DE 102 37 722.7  
*(if foreign priority is claimed)*
15.  Other: Application Data Sheet – 3 pages

#### CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

*(Insert Customer No. or Attach bar code label here)*

 B.18.03

Julie Anne Knight, Reg. No. 48,867

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3679  
Telefax (908) 231-2626  
Aventis Docket No. **DEAV2002/0063 US NP**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

**Complete if Known**

Application Number	Not Yet Assigned
Filing Date	August 18, 2003
First Named Inventor	RITZELER, et al.
Examiner Name	
Group / Art Unit	

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 750.00)

Attorney Docket No. DEAV2002/0063 US NP

**METHOD OF PAYMENT (check all that apply)**
 Check  Credit Card  Money  Other Order  None
 Deposit Account

Deposit Account Number

18-1982

Deposit Account Name

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

- Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1001	2001	750	750
1002	2002	330	
1003	2003	520	
1004	2004	750	
1005	2005	160	
<b>SUBTOTAL (1)</b>		<b>(\$750.00)</b>	

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

	Extra Claims	Fee from below	Fee Paid
Total Claims	14	-20**= 0 x 0 = 0	0
Independent Claims	1	- 3**= 0 x 0 = 0	0
Multiple Dependent		0 = 0	0

Large Entity	Small Entity	Fee Description
Fee Code	Fee Code	Fee (\$)
1202	2202	18 9
1201	2201	84 42
1203	2203	280 140
1204	2204	84 42
1205	2205	18 9
<b>SUBTOTAL (2)</b>		<b>(\$0.00)</b>


\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1051	2051	130 65	Surcharge - late filing fee or oath
1052	2052	50 25	Surcharge - late provisional filing fee or cover sheet
1053	1053	130 130	Non-English Specification
1812	1812	2,520 2,520	For filing a request for reexamination
1804	1804	920* 920*	Requesting publication of SIR prior to Examiner action
1805	1805	1,840* 1,840*	Requesting publication of SIR after Examiner action
1251	2251	110 55	Extension for reply within first month
1252	2252	410 205	Extension for reply within second month
1253	2253	930 465	Extension for reply within third month
1254	2254	1,450 725	Extension for reply within fourth month
1255	2255	1,970 985	Extension for reply within fifth month
1401	2401	320 160	Notice of Appeal
1402	2402	320 160	Filing a brief in support of an appeal
1403	2403	280 140	Request for oral hearing
1451	1451	1,510 1,510	Petition to institute a public use proceeding
1452	2452	110 55	Petition to revive - unavoidable
1453	2453	1,300 650	Petition to revive - unintentional
1501	2501	1,300 650	Utility issue fee (or reissue)
1502	2502	470 235	Design issue fee
1503	2503	630 315	Plant issue fee
1460	1460	130 130	Petitions to the Commissioner
1807	1807	50 50	Petitions related to provisional applications
1806	1806	180 180	Submission of Information Disclosure Stmt
8021	8021	40 40	Recording each patent assignment per property (times number of properties)
1809	2809	750 375	Filing a submission after final rejection (37 CFR § 1.129(a))
1810	2810	750 375	For each additional invention to be examined (37 CFR § 1.129(b))
1801	2801	750 375	Request for Continued Examination (RCE)
1802	1802	900 900	Request for expedited examination of a design application
Other fee (specify)			

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** (\$)**SUBMITTED BY****Complete (If applicable)**

Name (Print/Type)	Julie Anne Knight, Reg. No. 48,867	Registration No. (Attorney/Agent)	48,867	Telephone	(908) 231-3679
Signature				Date	8/18/03

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template